Login / Signup

Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.

Thomas ChevietIsabelle Lefebvre-TournierSharon WeinSuzanne Peyrottes
Published in: Journal of medicinal chemistry (2019)
Malaria still affects around 200 million people and is responsible for more than 400,000 deaths per year, mostly children in subequatorial areas. This disease is caused by parasites of the Plasmodium genus. Only a few WHO-recommended treatments are available to prevent or cure plasmodial infections, but genetic mutations in the causal parasites have led to onset of resistance against all commercial antimalarial drugs. New drugs and targets are being investigated to cope with this emerging problem, including enzymes belonging to the main metabolic pathways, while nucleoside and nucleotide analogues are also a promising class of potential drugs. This review highlights the main metabolic pathways targeted for the development of potential antiplasmodial therapies based on nucleos(t)ide analogues, as well as the different series of purine-containing nucleoside and nucleotide derivatives designed to inhibit Plasmodium falciparum purine metabolism.
Keyphrases
  • plasmodium falciparum
  • structure activity relationship
  • molecular docking
  • young adults
  • genome wide
  • human health
  • mass spectrometry
  • cancer therapy
  • risk assessment
  • gene expression
  • atomic force microscopy